SlideShare a Scribd company logo
1 of 120
Acute coronary syndrome
EPIDEMIOLGY
• Main cause of death
• The highest rate is in south India.
• It has been estimated that India had
the highest number of deaths in the
world due to CAD in 2002, nearly 1.5
million and which is expected to
double by 2015.
• Atherosclerosis remains the major
cause of death and premature
disability
MEANING
• Atherosclerosis :
athere=fatty
mush, skleros =
hard.
• Atherosclerosis
= “hardening of
the arteries”
MEANING
ACS
no ST
elevation
Unstable
angina
NSTEMI
ST
elevation
MI
Acute coronary syndrome
Coronary circulation
Coronary circulation
Risk factors
Non modifiable Risk Factors
• Heredity
• Age
• Personality factors
• Gender
Modifiable Risk Factors
• Smoking
• Hypertension
• Elevated serum cholesterol level
• Diabetes
• Obesity
• Physical Inactivity
Contributing Risk Factors
• Response to stress
• Homocysteine Level
• Inflammatory Level
• Menopause
• Type A Behavioural Patterns, TABP
• Hemostatic factors
Novel risk factors
• Homocysteine
• CRP
• Plasma fibrinogen
• Fibrin D dimer
• Lipoprotein
CAUSES OF ACS
• Decrease in the oxygen
available to the myocardium
– Nonobstructive clot on an
atherosclerotic plaque.
– Coronary vasospasm.
– Atherosclerotic obstruction
without clot or vasospasm.
– Inflammation or infection.
– Unstable angina due to a non
cardiac cause.
– Thrombus formation with
subsequent coronary artery
occlusion
CAUSES OF ACS
• Increase in the oxygen
demand
PATHOPHYSIOLOGY
• Initiation of Atherosclerosis
• Leukocyte Recruitment
• Foam-Cell Formation
• Atheroma Evolution and Complications
• Microvessels
• Calcification
• Plaque Evolution
Acute coronary syndrome
Acute coronary syndrome
Acute coronary syndrome
Deterioration of a stable
atherosclerotic plaque
Exposing the intima to blood
Stimulating platelet aggregation
Local vasoconstriction
Thrombus formation
Partially occluded by the thrombus
(manifesting UA/NSTEMI) or totally
occluded by a thrombus (STEMI)
A
C
S
A
C
S
Acute coronary syndrome
Acute coronary syndrome
Criteria for diagnosis of ACS
Major criteria Minor criteria
A diagnosis of ACS can be
made if one or more of the
following major criteria are
present:
 ST elevation or LBBB in
the setting of recent
(<24hrs) or ongoing
angina
 New or presumably new,
ST segment depression
(≥0.05mV) or T wave
inversion (≥ 0.2mV)
with rest symptoms
 Elevated serum markers
of myocardial damage
(ie, Troponin I, T and
CK-MB)
In the absence of a major criterion, a diagnosis of ACS requires
the presence of at least one item from both column 1 and 2
1 2
 Prolonged (ie, >20mts)
chest, arm/shoulder,
neck or epigastric
discomfort
 New onset chest, arm/
shoulder, neck, or
epigastric discomfort at
rest , minimal exertion or
ordinary activity
 Previously documented
chest, arm/ shoulder,
neck, or epigastric
discomfort which has
become distinctly more
frequent or longer in
duration
 Typical/ atypical angina
 Male> 40yrs or
female>60yrs
 Known CAD
 HF, hypotension or
transient mitral valve
regurgitation by
examination
 DM
 Extracardiac disease
 Pathologic Q wave on
ECG
 Abnormal ST segment or
T wave abnormalities
not known to be new
NSTE ACS
Definition
Stable angina pectoris is
characterized by chest or arm
discomfort that may not be
described as pain but is
reproducibly associated with
physical exertion or stress and is
relieved within 5–10 minutes by
rest and/or sublingual
nitroglycerin.
Unstable Angina is defined as angina
pectoris or equivalent ischemic
discomfort with at least one of three
features:
(1) it occurs at rest (or with minimal
exertion), usually lasting >10
minutes;
(2) it is severe and of new onset (i.e.,
within the prior 4–6 weeks); and/or
(3) it occurs with a crescendo pattern
The diagnosis of NSTEMI is
established if a patient with the
clinical features of UA develops
evidence of myocardial necrosis,
as reflected in elevated cardiac
biomarkers.
Canadian Cardiovascular
Society - Classification of
Angina
CLASS
ACTIVITY
EVOKING
ANGINA
LIMITS TO
ACTIVITY
I
II
III
IV
Prolonged
exertion
Walking>2
blocks
Walking<2
blocks
Minimal or rest
None
Slight
Marked
Severe
Pathophysiology
A reduction in oxygen supply and/or
by an increase in myocardial
oxygen demand superimposed on
a lesion that causes coronary
arterial obstruction, usually an
atherothrombotic coronary plaque
(1) plaque rupture or erosion with a
superimposed nonocclusive thrombus 
NSTEMI may occur with downstream
embolization of platelet aggregates and/or
atherosclerotic debris;
(2) dynamic obstruction [e.g., coronary spasm,
as in Prinzmetal's variant angina (PVA)
(3) progressive mechanical obstruction [e.g.,
rapidly advancing coronary atherosclerosis
or restenosis following percutaneous
coronary intervention (PCI)]
(4) UA secondary to increased myocardial
oxygen demand and/or decreased supply
(e.g., tachycardia, anemia).
Clinical Presentation
• Typical chest and associated
symptoms (not related to trauma):
Atypical symptoms
• Neck, throat, jaw or tooth discomfort
• Shoulder or arm pain
• Numbness or tingling in the chest or related area
• Fullness or burning in the chest
• Epigastric discomfort which is described as indigestion
• Discomfort between scapula or in the midback region
• Dizziness/ light headedness with or without syncope
• Fatigue or weakness not related to neurologic problems
• Palpitation of new onset with no history of dysrhythmia
• Mid back pain (not related to degenerative joint
diseases)
Diagnostic Pathways
• Clinical history
• ECG
• Cardiac markers
• Stress testing (coronary imaging is
an emerging option).
Clinical history
Electrocardiogram
Electrocardiogram
Biochemical cardiac markers
• Creatine kinase (CK-MB)
• Troponin I and T and/ or
• Myoglobulin
Medical Treatment
• Bed rest
• Continuous ECG monitoring for ST-
segment deviation and cardiac
arrhythmias.
• Ambulation is permitted if the
patient shows no recurrence of
ischemia and does not develop a
biomarker of necrosis for 12–24 h.
Acute coronary syndrome
Acute coronary syndrome
Acute coronary syndrome
Acute coronary syndrome
Acute coronary syndrome
TREATMENT
Medical
therapy
Anti-ischemic
treatment
Antithrombotic
treatment.
Anti-ischemic treatment
• To provide relief and prevention of
recurrence of chest pain
• Initial treatment should include
– bed rest
– nitrates, and
– beta blockers
Antithrombotic Therapy:
• Other main component of treatment
for UA/NSTEMI
• Initial treatment should begin with the
platelet cyclooxygenase inhibitor
aspirin.
• The typical initial dose is 325 mg/d,
with lower doses (75–162 mg/d)
recommended for long-term therapy.
Anticoagulant therapy
• Unfractionated heparin (UFH
• The low-molecular-weight heparin
(LMWH), enoxaparin
• The indirect Factor Xa inhibitor,
fondaparinux
• Bivalirudin
Unstable Angina Risk
Stratification
o Low risk
– New-onset exertional angina
– Minor chest pain during exercise
– Pain relieved promptly by nitroglycerine
o Management
– Can be managed safety as an outpatient
(assuming close follow-up and rapid
investigation)
Unstable Angina Risk
Stratification
o Intermediate risk
– Prolonged chest pain
– Diagnosis of rule-out MI
o Management
– Observe in the ER or Chest Pain Unit
– Monitor clinical status and ECG
– Obtain cardiac enzyme (troponin T or I) every
8 to 12 hours
Unstable Angina Risk
Stratification
o High risk
– Recurrent chest pain
– ST-segment change
– Hemodynamic compromise
– Elevation in cardiac enzyme
o Management
– Monitor in the coronary Care Unit
Risk Stratification by ECG
The risk of death or MI at 30 days is
stongly related to the ECG at the
time of chest pain
• ST depression 10 %
• T-wave inversion 5 %
• No ECG changes 1~2 %
PRINZMETAL'S VARIANT
ANGINA (PVA)
• A syndrome of severe ischemic
pain that occurs at rest but not
usually with exertion and is
associated with transient ST-
segment elevation.
• This syndrome is due to focal
spasm of an epicardial coronary
artery, leading to severe
myocardial ischemia
Clinical and Angiographic
Manifestations
Treatment of PVA
• Nitrates and calcium channel
blockers
• Aspirin may actually increase the
severity of ischemic episodes,
possibly as a result of the exquisite
sensitivity of coronary tone to
modest changes in the synthesis of
prostacyclin.
• The response to beta blockers is
variable.
• Coronary revascularization
MYOCARDIAL INFARCTION
(STEMI)
DEFINITION
• A dynamic process by which one
or more regions of the heart
experience a severe and prolonged
decrease in oxygen supply because
of insufficient coronary blood flow;
subsequently, necrosis or death•to
the myocardial tissue occurs.
Pathophysiology
slowly developing high
grade stenosis of
epicardial coronary
arteries
complete occlusion ,
but do not precipitate
MI
Development of
collateral circulation
atherosclerotic plaque
rupture
exposure of substances
that promote platelet
activation and
aggregation
thrombin generation
thrombus formation
interrupt blood supply
and leads imbalance
between O2 demand
and supply
myocardial necrosis
contractile function of
the heart stops at
necrotic area
• The coronary plaques prone to
disruption are those with a rich
lipid core and a thin fibrous cap.
disrupted plaque
Formation of an
initial platelet
monolayer
activation of various
agonists
promote platelet
activation
release of
thromboxane A2
further platelet
activation
potential resistance
to fibrinolysis
develops.
Platelet activation
change in the glycoprotein IIb/IIIa
receptor
develops a high affinity for soluble
adhesive proteins (i.e., integrins)
such as fibrinogen
platelet cross-linking and
aggregation
Disrupted plaque
exposure of tissue
factor in damaged
endothelial cells at the
site
coagulation cascade is
activated
Factors VII and X are
activated
the conversion of
prothrombin to
thrombin
converts fibrinogen to
fibrin
autoamplification
reaction
further activation of
the coagulation
cascade
Artery is occluded by a
thrombus containing
platelet aggregates and
fibrin strands.
The amount of myocardial
damage caused by coronary
occlusion depends on
(1) the territory supplied by the affected vessel
(2) whether or not the vessel becomes totally
occluded
(3) the duration of coronary occlusion
(4) the quantity of blood supplied by collateral vessels
to the affected tissue
(5) the demand for oxygen of the myocardium whose
blood supply has been suddenly limited
(6) endogenous factors that can produce early
spontaneous lysis of the occlusive thrombus, and
(7) the adequacy of myocardial perfusion in the
infarct zone when flow is restored in the occluded
epicardial coronary artery.
Location of Infarction
Location of MI Primary siteof occlusion
Inferior MI RCA (80-90%), LCX (10-
20%)
Inferolateral MI LCX
Posterior MI RCA/ LCX
Anterior MI LAD
Anterior septal
MI
LAD
Lateral MI LAD/LCX
Right ventricular RCA
KILLIPS CLASSIFICATION
Killip class
I
Individuals with no clinical signs of
heart failure
Killip class
II
Individuals withrales or crackles in the
lungs , an S3, and elevated JVP
Killip class
III
Individuals with frank acute pulmonary
edema
Killip class
IV
Individuals with cardiogenic shock/
hypotension and evidence of peripheral
vasoconstriction (oliguria, cyanosis or
sweating)
DEGREES OF DAMAGE
Involved layers of heart
muscle
– Transmural (Q wave) infarction - area
of necrosis occurs throughout the
entire thickness of the heart muscle.
– Subendocardial (nontransmural/non
Q-wave) infarction area of necrosis is
confined to the innermost layer of
the heart lining the chambers.
Clinical features
• Chest pain
Clinical features
• Diaphoresis, cool clammy skin, facial
pallor.
• Hypertension or hypotension and
Bradycardia or tachycardia
• Premature ventricular and/or atrial
beats
• Palpitations, severe anxiety, dyspnea
• Disorientation, confusion,
restlessness
• Fainting, marked weakness
• Nausea, vomiting, hiccups
Acute coronary syndrome
Atypical symptoms
• Epigastric or abdominal distress
• dull aching or tingling sensations
• shortness of breath
• extreme fatigue
Acute coronary syndrome
Physical Signs
• Fourth and third heart sounds
• Decreased intensity of the first
heart sound
• Paradoxical splitting of the second
heart sound
• A pericardial friction rub
(transmural STEMI)
• Temperature elevations up to
38°C.
Diagnostic Evaluation
(1) ECG
(2) serum cardiac biomarkers
(3) cardiac imaging
(4) nonspecific indices of tissue
necrosis and inflammation
Physical Examination
• muffling of sounds
• presence of gallop
• arrhythmia, and
• accentuation of pulmonary second
sound
WHO criteria for diagnosis of
MI:
It requires atleast two of the
following three elements
• A history of ischemic type chest
discomfort
• Evolutionary changes on serially
obtained ECG tracing
• Typical rise and fall in serum
cardiac markers
ECG Changes
– ST segment depression and T wave
inversion indicate a pattern of
ischemia.
– ST elevation indicates an injury
pattern.
– Q waves indicate tissue necrosis and
are permanent
Location of MI Primary siteof
occlusion
Primary ECG changes Complications
Inferior MI RCA (80-90%)
LCX (10-20%)
L II,III, aVF First and second degree
AV block, right
ventricular infarct
Inferolateral MI LCX L II, III, aVF, V5,V6 Third degree heart block,
left HF, CMP, left
ventricular rupture
Posterior MI RCA/ LCX No lead truly looks at
posterior surface. Look for
reciprocal changes in V1
and V2- tall, broad R
waves; ST depression and
tall T waves. Posterior
leads V7,V8 and V9 may
be recorded and evaluated
First, second, and third
degree heart block, HF,
bradydysrhythmias
Anterior MI LAD V2- V4 Third degree heart block,
HF, bundke branch block
Anterior septal
MI
LAD V1-V3 Second and third degree
heart block
Lateral MI LAD/LCX V5, V6, I, aVL HF
Right
ventricular
RCA V4R
Right precordial leads
V1R – V6R may be
recorded and evaluated
Increased RAP, decreased
CO, bradydysthymias,
heart blocks, hyptension,
cardiogenic shock
ECG leads showing changes Location of
infarct
V1-V3 Anteroseptal
V4- V6, L1 and aVL Anterolateral
aVF,L2 and L3, ST depression in
V1 and V2
Inferior wall
Presence of tall R wave and
upright T waves in V1 and V2
True posterior
infarct
ST elevation in Rt sided chest
leads and Q waves (V3R, V4R)
Right ventricular
infarct
Cardiac Markers
• Nonspecific markers
– lactate dehydrogenase
– aspartate aminotransferase
– myoglobin
• Specific cardiac markers
– Troponin (troponin C, troponin I and
troponin T).
– Creatine kinase (CK)
Marker Rise in
serum
level from
onset
Peak level Time to
return to
normal
Time for
blood
collection
SGOT (5-
40u/l)
8-12 hrs 18-36hrs 3-4 days Once n
12hrs
LDH (20-
220IU/L)
10hrs 24-48hrs 10- 14
days
24hrs
CK-MB 3-12hrs 24hrs 48-72 hrs Every
12hrs for 3
days
C TnT 3-12hrs 12hrs-2
days
5-14 days Once
atleast
every 12
hrs
C TnI 3-12hrs 24hrs 5-10days Once
atleast
every 12
hrs
Acute coronary syndrome
• Chest xray: Prominent pulmonary
vascular markings on x ray indicate
left ventricular failure. Chest film
helps to exclude other causes of
chest pain such as pneumothorax,
pulmonary infarction with effusion,
aortic dissection and skeletal
fractures.
• Echocardiogram:
– used to evaluate ventricular function.
– used to assist in diagnosing an MI,
especially when the ECG is
nondiagnostic.
Acute coronary syndrome
• CT Scan: to reveal cavity
dimensions, wall thickness,
aneurysms and intracardiac
thrombi.
• Nuclear imaging : to study nature
of myocardial lesion, its viability
and prognosis
• MRI scan: to assess the perfusion
of infracted and noninfarcted
tissue as well as the state of
reperfused myocardium
Other Findings
• Elevated CRP and lipoprotein
• Abnormal coagulation studies
• Elevated white blood cell (WBC) count
and sedimentation rate
• Radionuclide imaging allows recognition
of areas of decreased perfusion.
• PET determines the presence of
reversible heart muscle injury and
irreversible or necrotic tissue; extent to
which the injured heart muscle has
responded to treatment can also be
determined.
Management
• Prehospital care:
1) recognition of symptoms by the patient and
prompt seeking of medical attention;
(2) rapid deployment of an emergency medical
team capable of performing resuscitative
maneuvers, including defibrillation;
(3) expeditious transportation of the patient to
a hospital facility that is continuously staffed
by physicians and nurses skilled in managing
arrhythmias and providing advanced cardiac
life support; and
(4) expeditious implementation of reperfusion
therapy
Acute coronary syndrome
Acute coronary syndrome
Emergency department
• Goals:
– control of cardiac discomfort,
– rapid identification of patients who
are candidates for urgent reperfusion
therapy,
– triage of lower-risk patients to the
appropriate location in the hospital,
and
– avoidance of inappropriate discharge
of patients with STEMI.
• Aspirin : Rapid
inhibition of
cyclooxygenase-1 in
platelets followed
by a reduction of
thromboxane A2
• Supplemental O2:
when hypoxemia is
present, O2 should
be administered by
nasal prongs or face
mask (2–4 L/min)
for the first 6–12 h
after infarction
Control of Discomfort
• Sublingual nitroglycerin
• Morphine
• Intravenous beta blockers
Management Strategies:
Initial 12-lead ECG  ST-segment
elevation of at least 2 mm in 2
contiguous precordial leads and 1
mm in 2 adjacent limb leads is
present  a patient should be
considered a candidate for
reperfusion therapy
• Gold hour = first 60 mts. Total
ischemic time : 120 mts
Primary Percutaneous
Coronary Intervention
• PCI, usually angioplasty and/or
stenting without preceding
fibrinolysis, referred to as primary
PCI
• It is effective in restoring perfusion
in STEMI when carried out on an
emergency basis in the first few
hours of MI.
• Advantage:
– patients who have contraindications to fibrinolytic
therapy
– More effective than fibrinolysis in opening
occluded coronary arteries
PCI
• Indication:
– When the diagnosis is in doubt
– Cardiogenic shock is present
– Bleeding risk is increased, or
– Symptoms have been present for at
least 2–3 h when the clot is more
mature and less easily lysed by
fibrinolytic drugs.
Acute coronary syndrome
Fibrinolysis
• Ideally initiated within 30 min of
presentation (door-to-needle time
30 min).
• Goal of fibrinolysis is prompt
restoration of full coronary arterial
patency.
Fibrinolytic agents
• Tissue plasminogen activator (tPA),
streptokinase, tenecteplase (TNK), and
reteplase (rPA)
– First generation drugs- streptokinase,
urokinase
– Second generation- TPA, anioylated
plasminogen streptokinase
– Third generation- reteplase, TNK
• These drugs are promoting the
conversion of plasminogen to plasmin,
which subsequently lyses fibrinthrombi.
Thrombolysis in myocardial
infarction (TIMI) grading
system
• Grade 0 - Complete occlusion of the
infarct-related artery
• Grade 1 - Some penetration of the
contrast material beyond the point of
obstruction but without perfusion of the
distal coronary bed;
• Grade 2 - Perfusion of the entire infarct
vessel into the distal bed, but with flow
that is delayed compared with that of a
normal artery
• Grade 3 - Full perfusion of the infarct
vessel with normal flow
CONTRAINDICATIONS OF
FIBRINOLYSIS
• History of cerebrovascular
hemorrhage, a nonhemorrhagic
stroke or other cerebrovascular
event within the past year
• Suspicion of aortic dissection
• Active internal bleeding (excluding
menses).
• Advanced age associated with an
increase in hemorrhagic disorders
Relative contraindications:
• Current use of anticoagulants (INR- 2)
• A recent (<2 weeks) invasive or surgical procedure
or prolonged (>10 min) cardiopulmonary
resuscitation
• Known bleeding disorders
• Pregnancy
• A hemorrhagic ophthalmic condition (e.g.,
hemorrhagic diabetic retinopathy)
• Active peptic ulcer disease
• A history of severe hypertension that is currently
adequately controlled.
• Because of the risk of an allergic reaction, patients
should not receive streptokinase if that agent had
been received within the preceding five days to
two years.
Hospital Management
• Coronary Care Units
• Diet
• Bowel Management
• Sedation
Interventional Cardiology:
• Percutaneous transluminal
coronary angioplasty
• Intracoronary stent
Surgical Revascularization
• Coronary Artery Bypass Graft
• Minimal Invasive Coronary Artery
Surgery
• Transmyocardial revascularization
Cardiac Rehabilitation
• Medically supervised program
consisting of exercise training,
education on heart healthy living,
and counseling to reduce stress
and help patients return to an
active lifestyle and recover more
quickly
Components
• Physician-prescribed
exercise
• Cardiac risk factor
modification (education,
counseling and
behavioral intervention)
• Psychosocial assessment
• Outcomes assessment
• Individualized treatment
plan
Complications
• Ventricular Dysfunction and
Congestive Heart Failure
STEMI
left ventricle begins
to dilate results from
expansion of the
infarct
resulting in
disproportionate
thinning and
elongation of the
infarct zone
lengthening of the
noninfarcted
segments occurs
overall chamber
enlargement
HEART FAILURE
EARLY COMPLICATIONS
• Hypovolemia
• Cardiogenic Shock
• Right Ventricular Infarction
• Arrhythmias
• Ventricular Premature Beats
• Ventricular Tachycardia and
Fibrillation
• Sinus Bradycardia
LATE COMPLICATIONS
• Left Ventricular Aneurysm
• Dressler’s syndrome
• Shoulder hand syndrome
Nursing Management of MI
Nursing Assessment
• Gather information regarding the patient's chest
pain:
• Evaluate cognitive, behavioral, and emotional
status.
• Prior health status with emphasis on current
medications, allergies
• Analyze information for contraindications for
thrombolytic therapy and PCI.
• Gather information about presence or absence of
cardiac risk factors.
• Identify patient's social support system and
potential caregivers.
• Identify significant other's reaction to the crisis
situation.
• Acute pain related to decreased
blood supply to the myocardium
• Ineffective tissue perfusion :
cardiopulmonary related to
reduced coronary blood flow from
coronary thrombus and
atherosclerotic plaque
• Anxiety related to pain and fear of
death
• Risk for decreased cardiac output
related to decrease in LV function
• Activity intolerance related to
imbalance between oxygen
demand and supply
• Ineffective coping related to life
threatening diagnosis
• Risk for bleeding
HEALTH EDUCATION
BIBLIOGRAPHY
• Braunwald, Fauci,Kasper,Hauser,
Longo,Jameson. Harrison’s Principles of
Internal Medicine. 15th ed. Vol 1. New
York:McGraw-Hill;2001
• K.V Krishnadas. Textbook of Medicine. 5th
ed. Delhi: Jaypee brothers;2008
• Bonow. Mann. Zipes, Libby. Braunwald’s
Heart disease. 9th ed. India; Elsevier
publication; 2011.
• Joyce M Black, Jane Hokanson Hawks.
Medical Surgical Nursing. 8th ed. Vol-2.
India: Saunders Elsevier publishers; 2010
Acute coronary syndrome
Acute coronary syndrome

More Related Content

What's hot

What's hot (20)

Management of Cardiogenic shock
Management of Cardiogenic shockManagement of Cardiogenic shock
Management of Cardiogenic shock
 
Pulmonary Embolism
Pulmonary EmbolismPulmonary Embolism
Pulmonary Embolism
 
Cardiac arrhythmias
Cardiac arrhythmiasCardiac arrhythmias
Cardiac arrhythmias
 
Mitral valve stenosis powerpoint
Mitral valve stenosis powerpointMitral valve stenosis powerpoint
Mitral valve stenosis powerpoint
 
Cardiogenic shock
Cardiogenic shockCardiogenic shock
Cardiogenic shock
 
Pulmonary embolism ppt
Pulmonary embolism pptPulmonary embolism ppt
Pulmonary embolism ppt
 
Acute coronary syndrome
Acute coronary syndromeAcute coronary syndrome
Acute coronary syndrome
 
Aortic stenosis
Aortic stenosis Aortic stenosis
Aortic stenosis
 
Cardiomyopathy
CardiomyopathyCardiomyopathy
Cardiomyopathy
 
Constrictive pericarditis
Constrictive pericarditisConstrictive pericarditis
Constrictive pericarditis
 
VALVULAR HEART DISEASE
VALVULAR HEART DISEASEVALVULAR HEART DISEASE
VALVULAR HEART DISEASE
 
Pericardial effusion
Pericardial effusionPericardial effusion
Pericardial effusion
 
Unstable Angina Pectoris
Unstable Angina PectorisUnstable Angina Pectoris
Unstable Angina Pectoris
 
Arrythmia
ArrythmiaArrythmia
Arrythmia
 
ARDS ppt
ARDS pptARDS ppt
ARDS ppt
 
Ventricular tachycardia
Ventricular tachycardiaVentricular tachycardia
Ventricular tachycardia
 
Pericarditis
PericarditisPericarditis
Pericarditis
 
Myocarditis
MyocarditisMyocarditis
Myocarditis
 
Pulmonary edema
Pulmonary edemaPulmonary edema
Pulmonary edema
 
Cardiac tamponade
Cardiac tamponadeCardiac tamponade
Cardiac tamponade
 

Viewers also liked

Pathogenesis of Acute Coronary Syndromes
Pathogenesis of Acute Coronary SyndromesPathogenesis of Acute Coronary Syndromes
Pathogenesis of Acute Coronary SyndromesViduranga Edirisinghe
 
STEMI and Acute Coronary Syndromes
STEMI and Acute Coronary SyndromesSTEMI and Acute Coronary Syndromes
STEMI and Acute Coronary SyndromesRommie Duckworth
 
Acute Coronary Syndrome
Acute Coronary SyndromeAcute Coronary Syndrome
Acute Coronary SyndromeAhmed Azhad
 
Acute coronary syndrome(STEMI GUIDELINES AND RECENT ADVANCES)
Acute coronary syndrome(STEMI GUIDELINES AND RECENT ADVANCES)Acute coronary syndrome(STEMI GUIDELINES AND RECENT ADVANCES)
Acute coronary syndrome(STEMI GUIDELINES AND RECENT ADVANCES)Aditya Sarin
 
Acute coronary syndrome
Acute coronary syndrome Acute coronary syndrome
Acute coronary syndrome Dee Evardone
 
96091164 Slice Ct And Cerebral Atherosclerosis02
96091164 Slice Ct And Cerebral Atherosclerosis0296091164 Slice Ct And Cerebral Atherosclerosis02
96091164 Slice Ct And Cerebral Atherosclerosis02calaf0618
 
Acs – new biomarkers & role of newer anticoagulants
Acs – new biomarkers & role of newer anticoagulantsAcs – new biomarkers & role of newer anticoagulants
Acs – new biomarkers & role of newer anticoagulantsArindam Pande
 
4.sakina cardiac enzymes
4.sakina cardiac enzymes4.sakina cardiac enzymes
4.sakina cardiac enzymessakina hasan
 
Askep infeksi jantung (perikarditis, endokarditis dan miokarditis) AKPER PEMK...
Askep infeksi jantung (perikarditis, endokarditis dan miokarditis) AKPER PEMK...Askep infeksi jantung (perikarditis, endokarditis dan miokarditis) AKPER PEMK...
Askep infeksi jantung (perikarditis, endokarditis dan miokarditis) AKPER PEMK...Operator Warnet Vast Raha
 
Acute coronary syndrome
Acute coronary syndromeAcute coronary syndrome
Acute coronary syndromeLih Yin Chong
 
Dinamica de los ruidos cardiacos
Dinamica de los ruidos cardiacosDinamica de los ruidos cardiacos
Dinamica de los ruidos cardiacosIsrael García
 
Management of Acute Coronary Syndrome
Management of Acute Coronary Syndrome Management of Acute Coronary Syndrome
Management of Acute Coronary Syndrome Lavina Belayutham
 
Preoperative management
Preoperative managementPreoperative management
Preoperative managementAbeer Nakera
 
Acute coronary syndrome
Acute coronary syndromeAcute coronary syndrome
Acute coronary syndromeDolly Jazmi
 

Viewers also liked (20)

Acute Coronary Syndrome
Acute Coronary SyndromeAcute Coronary Syndrome
Acute Coronary Syndrome
 
Acute coronary syndrome
Acute coronary syndromeAcute coronary syndrome
Acute coronary syndrome
 
Pathogenesis of Acute Coronary Syndromes
Pathogenesis of Acute Coronary SyndromesPathogenesis of Acute Coronary Syndromes
Pathogenesis of Acute Coronary Syndromes
 
Acute Coronary Syndromes
Acute Coronary Syndromes Acute Coronary Syndromes
Acute Coronary Syndromes
 
Acute coronary syndrome
Acute coronary syndromeAcute coronary syndrome
Acute coronary syndrome
 
STEMI and Acute Coronary Syndromes
STEMI and Acute Coronary SyndromesSTEMI and Acute Coronary Syndromes
STEMI and Acute Coronary Syndromes
 
Skema nstemi
Skema nstemiSkema nstemi
Skema nstemi
 
Acute Coronary Syndrome
Acute Coronary SyndromeAcute Coronary Syndrome
Acute Coronary Syndrome
 
Acute coronary syndrome(STEMI GUIDELINES AND RECENT ADVANCES)
Acute coronary syndrome(STEMI GUIDELINES AND RECENT ADVANCES)Acute coronary syndrome(STEMI GUIDELINES AND RECENT ADVANCES)
Acute coronary syndrome(STEMI GUIDELINES AND RECENT ADVANCES)
 
Acute coronary syndrome
Acute coronary syndrome Acute coronary syndrome
Acute coronary syndrome
 
96091164 Slice Ct And Cerebral Atherosclerosis02
96091164 Slice Ct And Cerebral Atherosclerosis0296091164 Slice Ct And Cerebral Atherosclerosis02
96091164 Slice Ct And Cerebral Atherosclerosis02
 
Acs – new biomarkers & role of newer anticoagulants
Acs – new biomarkers & role of newer anticoagulantsAcs – new biomarkers & role of newer anticoagulants
Acs – new biomarkers & role of newer anticoagulants
 
4.sakina cardiac enzymes
4.sakina cardiac enzymes4.sakina cardiac enzymes
4.sakina cardiac enzymes
 
Cardiovascular ppt. fall 08 web v1
Cardiovascular ppt. fall 08 web v1Cardiovascular ppt. fall 08 web v1
Cardiovascular ppt. fall 08 web v1
 
Askep infeksi jantung (perikarditis, endokarditis dan miokarditis) AKPER PEMK...
Askep infeksi jantung (perikarditis, endokarditis dan miokarditis) AKPER PEMK...Askep infeksi jantung (perikarditis, endokarditis dan miokarditis) AKPER PEMK...
Askep infeksi jantung (perikarditis, endokarditis dan miokarditis) AKPER PEMK...
 
Acute coronary syndrome
Acute coronary syndromeAcute coronary syndrome
Acute coronary syndrome
 
Dinamica de los ruidos cardiacos
Dinamica de los ruidos cardiacosDinamica de los ruidos cardiacos
Dinamica de los ruidos cardiacos
 
Management of Acute Coronary Syndrome
Management of Acute Coronary Syndrome Management of Acute Coronary Syndrome
Management of Acute Coronary Syndrome
 
Preoperative management
Preoperative managementPreoperative management
Preoperative management
 
Acute coronary syndrome
Acute coronary syndromeAcute coronary syndrome
Acute coronary syndrome
 

Similar to Acute coronary syndrome

Myocardial Infraction -cardiac system disorder .pptx
Myocardial Infraction -cardiac system disorder .pptxMyocardial Infraction -cardiac system disorder .pptx
Myocardial Infraction -cardiac system disorder .pptxshiwani88
 
Coronary heart disease
Coronary heart diseaseCoronary heart disease
Coronary heart diseaseIvan Luyimbazi
 
Ischemic Heart Disease lecture.pptx
Ischemic Heart Disease lecture.pptxIschemic Heart Disease lecture.pptx
Ischemic Heart Disease lecture.pptxRaufAnnaby2
 
Coronary Artery Disease.ppt
Coronary Artery Disease.pptCoronary Artery Disease.ppt
Coronary Artery Disease.pptChanakTrikhatri1
 
7. Ischemic heart disease DBU.pptx
7. Ischemic heart disease DBU.pptx7. Ischemic heart disease DBU.pptx
7. Ischemic heart disease DBU.pptxMisaleHaile
 
lecture 3 Cardiac alteration
lecture 3 Cardiac alteration lecture 3 Cardiac alteration
lecture 3 Cardiac alteration ArabAlkhadam
 
Adult health 1 presentation-1.pptx
Adult health  1 presentation-1.pptxAdult health  1 presentation-1.pptx
Adult health 1 presentation-1.pptxSani191640
 
MUCLecture_2022_12319533. Medical surgical nursing pptx
MUCLecture_2022_12319533. Medical surgical nursing pptxMUCLecture_2022_12319533. Medical surgical nursing pptx
MUCLecture_2022_12319533. Medical surgical nursing pptxssuser47b89a
 
Angina Pectoris and Antianginal Drugs_Kamal.pptx
Angina Pectoris and Antianginal Drugs_Kamal.pptxAngina Pectoris and Antianginal Drugs_Kamal.pptx
Angina Pectoris and Antianginal Drugs_Kamal.pptxMuhammad Kamal Hossain
 
Acute Coronary Syndrome: MI
Acute Coronary Syndrome: MIAcute Coronary Syndrome: MI
Acute Coronary Syndrome: MIshristi shrestha
 
Management of MYOCARDIAL INFARCTION_081637.pptx
Management of MYOCARDIAL INFARCTION_081637.pptxManagement of MYOCARDIAL INFARCTION_081637.pptx
Management of MYOCARDIAL INFARCTION_081637.pptxubogunogheneakpobore
 
Myocardial Infarction
Myocardial InfarctionMyocardial Infarction
Myocardial Infarctionmoh kuwait
 
Acute Coronary Syndrome, Myocardial Infarction.
Acute Coronary Syndrome, Myocardial Infarction.Acute Coronary Syndrome, Myocardial Infarction.
Acute Coronary Syndrome, Myocardial Infarction.DR. VINAYAK BHOI
 
cadiovascular disorders:d isease models part ii
cadiovascular disorders:d isease models part iicadiovascular disorders:d isease models part ii
cadiovascular disorders:d isease models part iitwiggypiggy
 
Bems Kiran presentation1
Bems Kiran presentation1Bems Kiran presentation1
Bems Kiran presentation1Aamir Sharif
 
IHD- MI,Unstable Angina- Dr Sabu Augustine
IHD- MI,Unstable Angina- Dr Sabu AugustineIHD- MI,Unstable Angina- Dr Sabu Augustine
IHD- MI,Unstable Angina- Dr Sabu Augustinedrsabuaugustine
 
Angina Pectoris and MI.pptx
Angina Pectoris and MI.pptxAngina Pectoris and MI.pptx
Angina Pectoris and MI.pptxJoric Magusara
 

Similar to Acute coronary syndrome (20)

Myocardial Infraction -cardiac system disorder .pptx
Myocardial Infraction -cardiac system disorder .pptxMyocardial Infraction -cardiac system disorder .pptx
Myocardial Infraction -cardiac system disorder .pptx
 
Coronary heart disease
Coronary heart diseaseCoronary heart disease
Coronary heart disease
 
I s c h a e m i a
I s c h a e m i aI s c h a e m i a
I s c h a e m i a
 
Ischemic Heart Disease lecture.pptx
Ischemic Heart Disease lecture.pptxIschemic Heart Disease lecture.pptx
Ischemic Heart Disease lecture.pptx
 
Coronary Artery Disease.ppt
Coronary Artery Disease.pptCoronary Artery Disease.ppt
Coronary Artery Disease.ppt
 
7. Ischemic heart disease DBU.pptx
7. Ischemic heart disease DBU.pptx7. Ischemic heart disease DBU.pptx
7. Ischemic heart disease DBU.pptx
 
lecture 3 Cardiac alteration
lecture 3 Cardiac alteration lecture 3 Cardiac alteration
lecture 3 Cardiac alteration
 
Adult health 1 presentation-1.pptx
Adult health  1 presentation-1.pptxAdult health  1 presentation-1.pptx
Adult health 1 presentation-1.pptx
 
MUCLecture_2022_12319533. Medical surgical nursing pptx
MUCLecture_2022_12319533. Medical surgical nursing pptxMUCLecture_2022_12319533. Medical surgical nursing pptx
MUCLecture_2022_12319533. Medical surgical nursing pptx
 
Angina Pectoris and Antianginal Drugs_Kamal.pptx
Angina Pectoris and Antianginal Drugs_Kamal.pptxAngina Pectoris and Antianginal Drugs_Kamal.pptx
Angina Pectoris and Antianginal Drugs_Kamal.pptx
 
Acute Coronary Syndrome: MI
Acute Coronary Syndrome: MIAcute Coronary Syndrome: MI
Acute Coronary Syndrome: MI
 
Management of MYOCARDIAL INFARCTION_081637.pptx
Management of MYOCARDIAL INFARCTION_081637.pptxManagement of MYOCARDIAL INFARCTION_081637.pptx
Management of MYOCARDIAL INFARCTION_081637.pptx
 
Myocardial Infarction
Myocardial InfarctionMyocardial Infarction
Myocardial Infarction
 
7 ihd (2)
7 ihd (2)7 ihd (2)
7 ihd (2)
 
Acute Coronary Syndrome, Myocardial Infarction.
Acute Coronary Syndrome, Myocardial Infarction.Acute Coronary Syndrome, Myocardial Infarction.
Acute Coronary Syndrome, Myocardial Infarction.
 
cadiovascular disorders:d isease models part ii
cadiovascular disorders:d isease models part iicadiovascular disorders:d isease models part ii
cadiovascular disorders:d isease models part ii
 
Bems Kiran presentation1
Bems Kiran presentation1Bems Kiran presentation1
Bems Kiran presentation1
 
IHD- MI,Unstable Angina- Dr Sabu Augustine
IHD- MI,Unstable Angina- Dr Sabu AugustineIHD- MI,Unstable Angina- Dr Sabu Augustine
IHD- MI,Unstable Angina- Dr Sabu Augustine
 
Angina Pectoris and MI.pptx
Angina Pectoris and MI.pptxAngina Pectoris and MI.pptx
Angina Pectoris and MI.pptx
 
Acute Coronary Syndrome
Acute Coronary SyndromeAcute Coronary Syndrome
Acute Coronary Syndrome
 

Recently uploaded

AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 

Recently uploaded (20)

AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 

Acute coronary syndrome

  • 2. EPIDEMIOLGY • Main cause of death • The highest rate is in south India. • It has been estimated that India had the highest number of deaths in the world due to CAD in 2002, nearly 1.5 million and which is expected to double by 2015. • Atherosclerosis remains the major cause of death and premature disability
  • 3. MEANING • Atherosclerosis : athere=fatty mush, skleros = hard. • Atherosclerosis = “hardening of the arteries”
  • 9. Non modifiable Risk Factors • Heredity • Age • Personality factors • Gender
  • 10. Modifiable Risk Factors • Smoking • Hypertension • Elevated serum cholesterol level • Diabetes • Obesity • Physical Inactivity
  • 11. Contributing Risk Factors • Response to stress • Homocysteine Level • Inflammatory Level • Menopause • Type A Behavioural Patterns, TABP • Hemostatic factors
  • 12. Novel risk factors • Homocysteine • CRP • Plasma fibrinogen • Fibrin D dimer • Lipoprotein
  • 13. CAUSES OF ACS • Decrease in the oxygen available to the myocardium – Nonobstructive clot on an atherosclerotic plaque. – Coronary vasospasm. – Atherosclerotic obstruction without clot or vasospasm. – Inflammation or infection. – Unstable angina due to a non cardiac cause. – Thrombus formation with subsequent coronary artery occlusion
  • 14. CAUSES OF ACS • Increase in the oxygen demand
  • 15. PATHOPHYSIOLOGY • Initiation of Atherosclerosis • Leukocyte Recruitment • Foam-Cell Formation • Atheroma Evolution and Complications • Microvessels • Calcification • Plaque Evolution
  • 19. Deterioration of a stable atherosclerotic plaque Exposing the intima to blood Stimulating platelet aggregation Local vasoconstriction Thrombus formation Partially occluded by the thrombus (manifesting UA/NSTEMI) or totally occluded by a thrombus (STEMI) A C S A C S
  • 22. Criteria for diagnosis of ACS Major criteria Minor criteria A diagnosis of ACS can be made if one or more of the following major criteria are present:  ST elevation or LBBB in the setting of recent (<24hrs) or ongoing angina  New or presumably new, ST segment depression (≥0.05mV) or T wave inversion (≥ 0.2mV) with rest symptoms  Elevated serum markers of myocardial damage (ie, Troponin I, T and CK-MB) In the absence of a major criterion, a diagnosis of ACS requires the presence of at least one item from both column 1 and 2 1 2  Prolonged (ie, >20mts) chest, arm/shoulder, neck or epigastric discomfort  New onset chest, arm/ shoulder, neck, or epigastric discomfort at rest , minimal exertion or ordinary activity  Previously documented chest, arm/ shoulder, neck, or epigastric discomfort which has become distinctly more frequent or longer in duration  Typical/ atypical angina  Male> 40yrs or female>60yrs  Known CAD  HF, hypotension or transient mitral valve regurgitation by examination  DM  Extracardiac disease  Pathologic Q wave on ECG  Abnormal ST segment or T wave abnormalities not known to be new
  • 24. Definition Stable angina pectoris is characterized by chest or arm discomfort that may not be described as pain but is reproducibly associated with physical exertion or stress and is relieved within 5–10 minutes by rest and/or sublingual nitroglycerin.
  • 25. Unstable Angina is defined as angina pectoris or equivalent ischemic discomfort with at least one of three features: (1) it occurs at rest (or with minimal exertion), usually lasting >10 minutes; (2) it is severe and of new onset (i.e., within the prior 4–6 weeks); and/or (3) it occurs with a crescendo pattern
  • 26. The diagnosis of NSTEMI is established if a patient with the clinical features of UA develops evidence of myocardial necrosis, as reflected in elevated cardiac biomarkers.
  • 27. Canadian Cardiovascular Society - Classification of Angina CLASS ACTIVITY EVOKING ANGINA LIMITS TO ACTIVITY I II III IV Prolonged exertion Walking>2 blocks Walking<2 blocks Minimal or rest None Slight Marked Severe
  • 28. Pathophysiology A reduction in oxygen supply and/or by an increase in myocardial oxygen demand superimposed on a lesion that causes coronary arterial obstruction, usually an atherothrombotic coronary plaque
  • 29. (1) plaque rupture or erosion with a superimposed nonocclusive thrombus  NSTEMI may occur with downstream embolization of platelet aggregates and/or atherosclerotic debris; (2) dynamic obstruction [e.g., coronary spasm, as in Prinzmetal's variant angina (PVA) (3) progressive mechanical obstruction [e.g., rapidly advancing coronary atherosclerosis or restenosis following percutaneous coronary intervention (PCI)] (4) UA secondary to increased myocardial oxygen demand and/or decreased supply (e.g., tachycardia, anemia).
  • 30. Clinical Presentation • Typical chest and associated symptoms (not related to trauma):
  • 31. Atypical symptoms • Neck, throat, jaw or tooth discomfort • Shoulder or arm pain • Numbness or tingling in the chest or related area • Fullness or burning in the chest • Epigastric discomfort which is described as indigestion • Discomfort between scapula or in the midback region • Dizziness/ light headedness with or without syncope • Fatigue or weakness not related to neurologic problems • Palpitation of new onset with no history of dysrhythmia • Mid back pain (not related to degenerative joint diseases)
  • 32. Diagnostic Pathways • Clinical history • ECG • Cardiac markers • Stress testing (coronary imaging is an emerging option).
  • 36. Biochemical cardiac markers • Creatine kinase (CK-MB) • Troponin I and T and/ or • Myoglobulin
  • 37. Medical Treatment • Bed rest • Continuous ECG monitoring for ST- segment deviation and cardiac arrhythmias. • Ambulation is permitted if the patient shows no recurrence of ischemia and does not develop a biomarker of necrosis for 12–24 h.
  • 44. Anti-ischemic treatment • To provide relief and prevention of recurrence of chest pain • Initial treatment should include – bed rest – nitrates, and – beta blockers
  • 45. Antithrombotic Therapy: • Other main component of treatment for UA/NSTEMI • Initial treatment should begin with the platelet cyclooxygenase inhibitor aspirin. • The typical initial dose is 325 mg/d, with lower doses (75–162 mg/d) recommended for long-term therapy.
  • 46. Anticoagulant therapy • Unfractionated heparin (UFH • The low-molecular-weight heparin (LMWH), enoxaparin • The indirect Factor Xa inhibitor, fondaparinux • Bivalirudin
  • 47. Unstable Angina Risk Stratification o Low risk – New-onset exertional angina – Minor chest pain during exercise – Pain relieved promptly by nitroglycerine o Management – Can be managed safety as an outpatient (assuming close follow-up and rapid investigation)
  • 48. Unstable Angina Risk Stratification o Intermediate risk – Prolonged chest pain – Diagnosis of rule-out MI o Management – Observe in the ER or Chest Pain Unit – Monitor clinical status and ECG – Obtain cardiac enzyme (troponin T or I) every 8 to 12 hours
  • 49. Unstable Angina Risk Stratification o High risk – Recurrent chest pain – ST-segment change – Hemodynamic compromise – Elevation in cardiac enzyme o Management – Monitor in the coronary Care Unit
  • 50. Risk Stratification by ECG The risk of death or MI at 30 days is stongly related to the ECG at the time of chest pain • ST depression 10 % • T-wave inversion 5 % • No ECG changes 1~2 %
  • 51. PRINZMETAL'S VARIANT ANGINA (PVA) • A syndrome of severe ischemic pain that occurs at rest but not usually with exertion and is associated with transient ST- segment elevation. • This syndrome is due to focal spasm of an epicardial coronary artery, leading to severe myocardial ischemia
  • 53. Treatment of PVA • Nitrates and calcium channel blockers • Aspirin may actually increase the severity of ischemic episodes, possibly as a result of the exquisite sensitivity of coronary tone to modest changes in the synthesis of prostacyclin. • The response to beta blockers is variable. • Coronary revascularization
  • 55. DEFINITION • A dynamic process by which one or more regions of the heart experience a severe and prolonged decrease in oxygen supply because of insufficient coronary blood flow; subsequently, necrosis or death•to the myocardial tissue occurs.
  • 56. Pathophysiology slowly developing high grade stenosis of epicardial coronary arteries complete occlusion , but do not precipitate MI Development of collateral circulation atherosclerotic plaque rupture exposure of substances that promote platelet activation and aggregation thrombin generation thrombus formation interrupt blood supply and leads imbalance between O2 demand and supply myocardial necrosis contractile function of the heart stops at necrotic area
  • 57. • The coronary plaques prone to disruption are those with a rich lipid core and a thin fibrous cap. disrupted plaque Formation of an initial platelet monolayer activation of various agonists promote platelet activation release of thromboxane A2 further platelet activation potential resistance to fibrinolysis develops.
  • 58. Platelet activation change in the glycoprotein IIb/IIIa receptor develops a high affinity for soluble adhesive proteins (i.e., integrins) such as fibrinogen platelet cross-linking and aggregation
  • 59. Disrupted plaque exposure of tissue factor in damaged endothelial cells at the site coagulation cascade is activated Factors VII and X are activated the conversion of prothrombin to thrombin converts fibrinogen to fibrin autoamplification reaction further activation of the coagulation cascade Artery is occluded by a thrombus containing platelet aggregates and fibrin strands.
  • 60. The amount of myocardial damage caused by coronary occlusion depends on (1) the territory supplied by the affected vessel (2) whether or not the vessel becomes totally occluded (3) the duration of coronary occlusion (4) the quantity of blood supplied by collateral vessels to the affected tissue (5) the demand for oxygen of the myocardium whose blood supply has been suddenly limited (6) endogenous factors that can produce early spontaneous lysis of the occlusive thrombus, and (7) the adequacy of myocardial perfusion in the infarct zone when flow is restored in the occluded epicardial coronary artery.
  • 61. Location of Infarction Location of MI Primary siteof occlusion Inferior MI RCA (80-90%), LCX (10- 20%) Inferolateral MI LCX Posterior MI RCA/ LCX Anterior MI LAD Anterior septal MI LAD Lateral MI LAD/LCX Right ventricular RCA
  • 62. KILLIPS CLASSIFICATION Killip class I Individuals with no clinical signs of heart failure Killip class II Individuals withrales or crackles in the lungs , an S3, and elevated JVP Killip class III Individuals with frank acute pulmonary edema Killip class IV Individuals with cardiogenic shock/ hypotension and evidence of peripheral vasoconstriction (oliguria, cyanosis or sweating)
  • 64. Involved layers of heart muscle – Transmural (Q wave) infarction - area of necrosis occurs throughout the entire thickness of the heart muscle. – Subendocardial (nontransmural/non Q-wave) infarction area of necrosis is confined to the innermost layer of the heart lining the chambers.
  • 66. Clinical features • Diaphoresis, cool clammy skin, facial pallor. • Hypertension or hypotension and Bradycardia or tachycardia • Premature ventricular and/or atrial beats • Palpitations, severe anxiety, dyspnea • Disorientation, confusion, restlessness • Fainting, marked weakness • Nausea, vomiting, hiccups
  • 68. Atypical symptoms • Epigastric or abdominal distress • dull aching or tingling sensations • shortness of breath • extreme fatigue
  • 70. Physical Signs • Fourth and third heart sounds • Decreased intensity of the first heart sound • Paradoxical splitting of the second heart sound • A pericardial friction rub (transmural STEMI) • Temperature elevations up to 38°C.
  • 71. Diagnostic Evaluation (1) ECG (2) serum cardiac biomarkers (3) cardiac imaging (4) nonspecific indices of tissue necrosis and inflammation
  • 72. Physical Examination • muffling of sounds • presence of gallop • arrhythmia, and • accentuation of pulmonary second sound
  • 73. WHO criteria for diagnosis of MI: It requires atleast two of the following three elements • A history of ischemic type chest discomfort • Evolutionary changes on serially obtained ECG tracing • Typical rise and fall in serum cardiac markers
  • 74. ECG Changes – ST segment depression and T wave inversion indicate a pattern of ischemia. – ST elevation indicates an injury pattern. – Q waves indicate tissue necrosis and are permanent
  • 75. Location of MI Primary siteof occlusion Primary ECG changes Complications Inferior MI RCA (80-90%) LCX (10-20%) L II,III, aVF First and second degree AV block, right ventricular infarct Inferolateral MI LCX L II, III, aVF, V5,V6 Third degree heart block, left HF, CMP, left ventricular rupture Posterior MI RCA/ LCX No lead truly looks at posterior surface. Look for reciprocal changes in V1 and V2- tall, broad R waves; ST depression and tall T waves. Posterior leads V7,V8 and V9 may be recorded and evaluated First, second, and third degree heart block, HF, bradydysrhythmias Anterior MI LAD V2- V4 Third degree heart block, HF, bundke branch block Anterior septal MI LAD V1-V3 Second and third degree heart block Lateral MI LAD/LCX V5, V6, I, aVL HF Right ventricular RCA V4R Right precordial leads V1R – V6R may be recorded and evaluated Increased RAP, decreased CO, bradydysthymias, heart blocks, hyptension, cardiogenic shock
  • 76. ECG leads showing changes Location of infarct V1-V3 Anteroseptal V4- V6, L1 and aVL Anterolateral aVF,L2 and L3, ST depression in V1 and V2 Inferior wall Presence of tall R wave and upright T waves in V1 and V2 True posterior infarct ST elevation in Rt sided chest leads and Q waves (V3R, V4R) Right ventricular infarct
  • 77. Cardiac Markers • Nonspecific markers – lactate dehydrogenase – aspartate aminotransferase – myoglobin • Specific cardiac markers – Troponin (troponin C, troponin I and troponin T). – Creatine kinase (CK)
  • 78. Marker Rise in serum level from onset Peak level Time to return to normal Time for blood collection SGOT (5- 40u/l) 8-12 hrs 18-36hrs 3-4 days Once n 12hrs LDH (20- 220IU/L) 10hrs 24-48hrs 10- 14 days 24hrs CK-MB 3-12hrs 24hrs 48-72 hrs Every 12hrs for 3 days C TnT 3-12hrs 12hrs-2 days 5-14 days Once atleast every 12 hrs C TnI 3-12hrs 24hrs 5-10days Once atleast every 12 hrs
  • 80. • Chest xray: Prominent pulmonary vascular markings on x ray indicate left ventricular failure. Chest film helps to exclude other causes of chest pain such as pneumothorax, pulmonary infarction with effusion, aortic dissection and skeletal fractures. • Echocardiogram: – used to evaluate ventricular function. – used to assist in diagnosing an MI, especially when the ECG is nondiagnostic.
  • 82. • CT Scan: to reveal cavity dimensions, wall thickness, aneurysms and intracardiac thrombi. • Nuclear imaging : to study nature of myocardial lesion, its viability and prognosis • MRI scan: to assess the perfusion of infracted and noninfarcted tissue as well as the state of reperfused myocardium
  • 83. Other Findings • Elevated CRP and lipoprotein • Abnormal coagulation studies • Elevated white blood cell (WBC) count and sedimentation rate • Radionuclide imaging allows recognition of areas of decreased perfusion. • PET determines the presence of reversible heart muscle injury and irreversible or necrotic tissue; extent to which the injured heart muscle has responded to treatment can also be determined.
  • 84. Management • Prehospital care: 1) recognition of symptoms by the patient and prompt seeking of medical attention; (2) rapid deployment of an emergency medical team capable of performing resuscitative maneuvers, including defibrillation; (3) expeditious transportation of the patient to a hospital facility that is continuously staffed by physicians and nurses skilled in managing arrhythmias and providing advanced cardiac life support; and (4) expeditious implementation of reperfusion therapy
  • 87. Emergency department • Goals: – control of cardiac discomfort, – rapid identification of patients who are candidates for urgent reperfusion therapy, – triage of lower-risk patients to the appropriate location in the hospital, and – avoidance of inappropriate discharge of patients with STEMI.
  • 88. • Aspirin : Rapid inhibition of cyclooxygenase-1 in platelets followed by a reduction of thromboxane A2 • Supplemental O2: when hypoxemia is present, O2 should be administered by nasal prongs or face mask (2–4 L/min) for the first 6–12 h after infarction
  • 89. Control of Discomfort • Sublingual nitroglycerin • Morphine • Intravenous beta blockers
  • 90. Management Strategies: Initial 12-lead ECG  ST-segment elevation of at least 2 mm in 2 contiguous precordial leads and 1 mm in 2 adjacent limb leads is present  a patient should be considered a candidate for reperfusion therapy • Gold hour = first 60 mts. Total ischemic time : 120 mts
  • 91. Primary Percutaneous Coronary Intervention • PCI, usually angioplasty and/or stenting without preceding fibrinolysis, referred to as primary PCI • It is effective in restoring perfusion in STEMI when carried out on an emergency basis in the first few hours of MI.
  • 92. • Advantage: – patients who have contraindications to fibrinolytic therapy – More effective than fibrinolysis in opening occluded coronary arteries
  • 93. PCI • Indication: – When the diagnosis is in doubt – Cardiogenic shock is present – Bleeding risk is increased, or – Symptoms have been present for at least 2–3 h when the clot is more mature and less easily lysed by fibrinolytic drugs.
  • 95. Fibrinolysis • Ideally initiated within 30 min of presentation (door-to-needle time 30 min). • Goal of fibrinolysis is prompt restoration of full coronary arterial patency.
  • 96. Fibrinolytic agents • Tissue plasminogen activator (tPA), streptokinase, tenecteplase (TNK), and reteplase (rPA) – First generation drugs- streptokinase, urokinase – Second generation- TPA, anioylated plasminogen streptokinase – Third generation- reteplase, TNK • These drugs are promoting the conversion of plasminogen to plasmin, which subsequently lyses fibrinthrombi.
  • 97. Thrombolysis in myocardial infarction (TIMI) grading system • Grade 0 - Complete occlusion of the infarct-related artery • Grade 1 - Some penetration of the contrast material beyond the point of obstruction but without perfusion of the distal coronary bed; • Grade 2 - Perfusion of the entire infarct vessel into the distal bed, but with flow that is delayed compared with that of a normal artery • Grade 3 - Full perfusion of the infarct vessel with normal flow
  • 98. CONTRAINDICATIONS OF FIBRINOLYSIS • History of cerebrovascular hemorrhage, a nonhemorrhagic stroke or other cerebrovascular event within the past year • Suspicion of aortic dissection • Active internal bleeding (excluding menses). • Advanced age associated with an increase in hemorrhagic disorders
  • 99. Relative contraindications: • Current use of anticoagulants (INR- 2) • A recent (<2 weeks) invasive or surgical procedure or prolonged (>10 min) cardiopulmonary resuscitation • Known bleeding disorders • Pregnancy • A hemorrhagic ophthalmic condition (e.g., hemorrhagic diabetic retinopathy) • Active peptic ulcer disease • A history of severe hypertension that is currently adequately controlled. • Because of the risk of an allergic reaction, patients should not receive streptokinase if that agent had been received within the preceding five days to two years.
  • 100. Hospital Management • Coronary Care Units • Diet • Bowel Management • Sedation
  • 101. Interventional Cardiology: • Percutaneous transluminal coronary angioplasty • Intracoronary stent
  • 102. Surgical Revascularization • Coronary Artery Bypass Graft • Minimal Invasive Coronary Artery Surgery • Transmyocardial revascularization
  • 103. Cardiac Rehabilitation • Medically supervised program consisting of exercise training, education on heart healthy living, and counseling to reduce stress and help patients return to an active lifestyle and recover more quickly
  • 104. Components • Physician-prescribed exercise • Cardiac risk factor modification (education, counseling and behavioral intervention) • Psychosocial assessment • Outcomes assessment • Individualized treatment plan
  • 105. Complications • Ventricular Dysfunction and Congestive Heart Failure STEMI left ventricle begins to dilate results from expansion of the infarct resulting in disproportionate thinning and elongation of the infarct zone lengthening of the noninfarcted segments occurs overall chamber enlargement HEART FAILURE
  • 106. EARLY COMPLICATIONS • Hypovolemia • Cardiogenic Shock • Right Ventricular Infarction • Arrhythmias • Ventricular Premature Beats • Ventricular Tachycardia and Fibrillation • Sinus Bradycardia
  • 107. LATE COMPLICATIONS • Left Ventricular Aneurysm • Dressler’s syndrome • Shoulder hand syndrome
  • 109. Nursing Assessment • Gather information regarding the patient's chest pain: • Evaluate cognitive, behavioral, and emotional status. • Prior health status with emphasis on current medications, allergies • Analyze information for contraindications for thrombolytic therapy and PCI. • Gather information about presence or absence of cardiac risk factors. • Identify patient's social support system and potential caregivers. • Identify significant other's reaction to the crisis situation.
  • 110. • Acute pain related to decreased blood supply to the myocardium
  • 111. • Ineffective tissue perfusion : cardiopulmonary related to reduced coronary blood flow from coronary thrombus and atherosclerotic plaque
  • 112. • Anxiety related to pain and fear of death
  • 113. • Risk for decreased cardiac output related to decrease in LV function
  • 114. • Activity intolerance related to imbalance between oxygen demand and supply
  • 115. • Ineffective coping related to life threatening diagnosis
  • 116. • Risk for bleeding
  • 118. BIBLIOGRAPHY • Braunwald, Fauci,Kasper,Hauser, Longo,Jameson. Harrison’s Principles of Internal Medicine. 15th ed. Vol 1. New York:McGraw-Hill;2001 • K.V Krishnadas. Textbook of Medicine. 5th ed. Delhi: Jaypee brothers;2008 • Bonow. Mann. Zipes, Libby. Braunwald’s Heart disease. 9th ed. India; Elsevier publication; 2011. • Joyce M Black, Jane Hokanson Hawks. Medical Surgical Nursing. 8th ed. Vol-2. India: Saunders Elsevier publishers; 2010